Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Regeneron Pharmaceuticals alleging securities fraud. The complaint claims the company made materially false statements regarding its Phase III Fianlimab-Libtayo study, including flawed statistical assumptions and failure to disclose that the study was unlikely to achieve its primary endpoint. Investors who purchased Regeneron securities between August 1, 2025 and May 15, 2026 are eligible to join the case.